Nucleolin as the earliest target molecule of autoantibodies produced in MRL/lpr lupus-prone mice

被引:20
|
作者
Hirata, D [1 ]
Iwamoto, M [1 ]
Yoshio, T [1 ]
Okazaki, H [1 ]
Masuyama, J [1 ]
Mimori, A [1 ]
Minota, S [1 ]
机构
[1] Jichi Med Sch, Div Clin Immunol & Rheumatol, Minami Kawachi, Tochigi 3290498, Japan
关键词
rodent; lupus; autoimmunity; autoantibodies; nucleolin;
D O I
10.1006/clim.2000.4916
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To elucidate the autoantigen against which autoantibodies are produced in the earliest phase of the disease:process of systemic lupus erythematosus (SLE), serum samples were collected individually and serially from 10 NZB/NZW F1 and 10 MRL/lpr mice. Using immunoblots with mouse thymoma cell (EL-4) lysates as substrates, all mice were found to generate autoantibody against an either 150-kDa, 110-kDa, 75-kDa, or 55 kDa molecule in as early as 4 weeks. Anti-DNA antibodies occurred almost at the same time or after those against these four molecules. The number of antigens reactive with autoantibodies in immunoblots increased gradually with age. Antibodies against histone molecules were produced after 8 weeks of age. Among the four antigens, the 110-kDa molecule was identified as nucleolin, which is an abundant nucleolar phosphoprotein. Nucleolin binds DNA, RNA, and nucleic acid-binding proteins such as histone H1. Nucleolin is a target of granzyme A of cytotoxic T cells, and autoantibodies against it are found in sera from patients with SLE as well as from those with various viral infections. These results indicate that nucleolin is one of the immunodominant molecules that break down self-tolerance and initiate autoantibody-spreading in a mouse model of SLE. (C) 2000 Academic Press.
引用
收藏
页码:50 / 58
页数:9
相关论文
共 50 条
  • [1] Nucleolin as one of the earliest targets of autoantibodies produced in NZB/W Fl and MRL/lpr lupus-prone mice.
    Hirata, D
    Iwamoto, M
    Okazaki, H
    Kano, S
    Minota, S
    [J]. ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S254 - S254
  • [2] Receptor editing is impaired in lupus-prone MRL/lpr mice
    Feeney, Ann J.
    Lamoureux, Jennifer
    Nemazee, David
    Watson, Lisa
    [J]. JOURNAL OF IMMUNOLOGY, 2006, 176 : S152 - S152
  • [3] Therapeutic Effects of Triptolide on Lupus-prone MRL/lpr Mice
    Huang, Xueqin
    Wen, Chengping
    Wei, Hua
    [J]. INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2018, 14 (05) : 681 - 688
  • [4] Fate of immune deposits in lupus-prone MRL/Mp lpr/lpr mice
    Cruse, JM
    Lewis, RE
    Dilioglou, S
    [J]. FASEB JOURNAL, 2000, 14 (06): : A1208 - A1208
  • [5] Depression is an early disease manifestation in lupus-prone MRL/lpr mice
    Gao, Hua-Xin
    Campbell, Sean R.
    Cui, Min-Hui
    Zong, Pu
    Hee-Hwang, Jong
    Gulinello, Maria
    Putterman, Chaim
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2009, 207 (1-2) : 45 - 56
  • [6] Treatment of Lupus-prone MRL-lpr Mice with the Mitochondrial Antioxidant MitoQ
    Budd, Ralph
    Fortner, Karen
    Blanco, Luz
    Kaplan, Mariana
    Perl, Andras
    Busliewicz, Iwona
    MacPherson, Greg
    Murphy, Mike
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [7] Mitochondrial Dysfunction in the Liver of Lupus-Prone MRL/Lpr Mice Prior to Disease Onset
    Oaks, Zachary A.
    Telarico, Tiffany
    Perl, Andras
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S624 - S625
  • [8] Therapeutic effect of dihydroartemisinin on lupus-prone MRL/lpr mice and its mechanism of action
    Jiang, A'pei
    Pan, Jieli
    Jiang, Fusheng
    Li, Meiya
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (08): : 9839 - 9844
  • [9] The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice
    Shi, Yu
    Yao, Wen
    Sun, Li
    Li, Guomin
    Liu, Haimei
    Ding, Peipei
    Hu, Weiguo
    Xu, Hong
    [J]. BMC NEPHROLOGY, 2019, 20 (01)
  • [10] The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice
    Yu Shi
    Wen Yao
    Li Sun
    Guomin Li
    Haimei Liu
    Peipei Ding
    Weiguo Hu
    Hong Xu
    [J]. BMC Nephrology, 20